| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/25/2013 | US8470364 Once daily formulations of tetracyclines |
| 06/25/2013 | US8470357 Methods of treatment with Syk inhibitors |
| 06/25/2013 | US8470346 Anti-viral pharmaceutical compositions |
| 06/25/2013 | US8470345 Lipids containing omega-3 and omega-6 fatty acids |
| 06/25/2013 | US8470344 Aqueous dispersions and solutions of difficult to dissolve materials and methods of their preparation |
| 06/25/2013 | US8470306 Crosslinked polysiloxanes, a process for their preparation and use of the crosslinked polysiloxanes in emulsifier systems for water-in-oil emulsions |
| 06/25/2013 | US8470301 Particulate materials |
| 06/25/2013 | US8469934 Pulsatile peri-corneal drug delivery device |
| 06/25/2013 | CA2747424C 1-heterodiene derivative and harmful organism control agent |
| 06/25/2013 | CA2744714C Amino pyrazole compound |
| 06/25/2013 | CA2725425C Homocysteine synthase inhibitor |
| 06/25/2013 | CA2724774C Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| 06/25/2013 | CA2719243C Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same |
| 06/25/2013 | CA2705312C Inhibitors of human immunodeficiency virus replication |
| 06/25/2013 | CA2702437C Method of delaying the onset of clinically definite multiple sclerosis |
| 06/25/2013 | CA2693537C Macrocyclic indole derivatives for the treatment of hepatitis c infections |
| 06/25/2013 | CA2692295C Combined use of methylol-transfer agents and fas-ligands in the treatment of cancer |
| 06/25/2013 | CA2686312C Process for preparing aromatase inhibitors |
| 06/25/2013 | CA2679315C Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy |
| 06/25/2013 | CA2677394C Skin-compatible virucidal composition |
| 06/25/2013 | CA2654210C Association of a sinus current inhibitor if and a beta blocker |
| 06/25/2013 | CA2653566C Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 06/25/2013 | CA2647512C Substance exhibiting neuromodulator activity |
| 06/25/2013 | CA2633074C Elongase genes and uses thereof |
| 06/25/2013 | CA2632842C Process for preparation of water-soluble azole prodrugs |
| 06/25/2013 | CA2627598C Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| 06/25/2013 | CA2599236C Crystalline forms of a biphenyl compound |
| 06/25/2013 | CA2598988C Cyclohepta[b]pyridine-3-carbonylguanidine derivative and pharmaceutical product containing the same as nhe inhibitors |
| 06/25/2013 | CA2595290C Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp |
| 06/25/2013 | CA2591912C Pyrimidinylisoxazole derivatives |
| 06/25/2013 | CA2588963C 1-substituted-3-.beta.-d-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same |
| 06/25/2013 | CA2588445C Pharmaceutical formulation containing a release rate controlling composition |
| 06/25/2013 | CA2585852C Dye-free pharmaceutical suspensions and related methods |
| 06/25/2013 | CA2585316C Benzothiazole formulations and use thereof |
| 06/25/2013 | CA2583642C Transdermal delivery systems |
| 06/25/2013 | CA2579583C Silver dihydrogen citrate compositions |
| 06/25/2013 | CA2577446C 2-arylcarbamoyl-indoles as cytokine inhibitors |
| 06/25/2013 | CA2576850C Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 06/25/2013 | CA2570264C 3-aminoindazoles |
| 06/25/2013 | CA2568632C Levodopa prodrugs, and compositions and uses thereof |
| 06/25/2013 | CA2564161C Melatonin and its use in preventing postoperative complications |
| 06/25/2013 | CA2557801C Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
| 06/25/2013 | CA2557161C Pharmaceutical composition comprising pimobendan |
| 06/25/2013 | CA2553884C Nutritional composition for improving skin condition and preventing skin diseases |
| 06/25/2013 | CA2551611C Thiazole derivatives for treating or preventing parkinson's disease |
| 06/25/2013 | CA2542434C Combination of flupirtine and tolperisone or eperisone for the treatment of painful conditions |
| 06/25/2013 | CA2536052C Novel crystalline compounds |
| 06/25/2013 | CA2535810C Tablet containing 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester or the salts thereof |
| 06/25/2013 | CA2524048C Immunosuppressant compounds and compositions |
| 06/25/2013 | CA2521885C Once daily formulations of tetracyclines |
| 06/25/2013 | CA2511881C Pharmaceutical compositions comprising a sodium salt of celecoxib with improved dissolution |
| 06/25/2013 | CA2506704C Peritoneal dialysis method |
| 06/25/2013 | CA2496459C 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
| 06/25/2013 | CA2482464C Oil body associated protein compositions and methods of use thereof for reducing the risk of cardiovascular disease |
| 06/25/2013 | CA2458798C Method for reducing hypertension and heart failure |
| 06/25/2013 | CA2444894C Sustained release drug delivery system containing codrugs |
| 06/25/2013 | CA2428744C Inhibition of lysozyme in treating sepsis-induced myocardial dysfunction |
| 06/25/2013 | CA2407808C Cyclipostins, process for their preparation and use thereof |
| 06/25/2013 | CA2405378C Stable taurolidine electrolyte solutions |
| 06/25/2013 | CA2380940C Substances and agents for positively influencing collagen |
| 06/25/2013 | CA2328520C Use of anti-prolactin agents to treat proliferative conditions |
| 06/25/2013 | CA2285241C Substituted 3-cyano quinolines |
| 06/25/2013 | CA2214453C Novel avian cytokines and genetic sequences encoding same |
| 06/20/2013 | WO2013090929A1 Amino quinoline derivatives inhibitors of hcv |
| 06/20/2013 | WO2013090871A1 Vaginal drug delivery devices and manufacturing methods |
| 06/20/2013 | WO2013090840A1 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors |
| 06/20/2013 | WO2013090836A1 Fluorinated estrogen receptor modulators and uses thereof |
| 06/20/2013 | WO2013090833A1 Angiotensins for treatment of fibrosis |
| 06/20/2013 | WO2013090829A1 Estrogen receptor modulators and uses thereof |
| 06/20/2013 | WO2013090776A1 Inhibition of axl/gas6 signaling in the treatment of disease |
| 06/20/2013 | WO2013090766A1 Uses of 3'-desferrithiocin analogs |
| 06/20/2013 | WO2013090750A1 Uses of 4'-desferrithiocin analogs |
| 06/20/2013 | WO2013090732A2 Collateral gene inactivation biomarkers and targets for cancer therapy |
| 06/20/2013 | WO2013090725A1 NOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF |
| 06/20/2013 | WO2013090722A1 Trpc4 modulators for use in the treatment or prevention of pain |
| 06/20/2013 | WO2013090666A1 Compositions containing kinase inhibitors |
| 06/20/2013 | WO2013090634A1 Use of polymeric excipients for lyophilization or freezing of particles |
| 06/20/2013 | WO2013090616A1 Autoimmune disorder treatment using rxr agonists |
| 06/20/2013 | WO2013090602A2 Rapamycin composition |
| 06/20/2013 | WO2013090557A2 Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders |
| 06/20/2013 | WO2013090550A1 Novel glycoside compounds |
| 06/20/2013 | WO2013090524A1 Compositions associated with and methods of managing neutrophil movement using serum amyloid p (sap) |
| 06/20/2013 | WO2013090497A1 Heterocyclic compounds as imaging probes of tau pathology |
| 06/20/2013 | WO2013090490A1 Tofacitinib salts |
| 06/20/2013 | WO2013090461A1 Statin bioavailability enhancement delivery composition |
| 06/20/2013 | WO2013090460A1 Solubilization and bioavailability of acetaminophen |
| 06/20/2013 | WO2013090454A2 Novel glp-1 receptor modulators |
| 06/20/2013 | WO2013090420A2 Fatty acid antiviral conjugates and their uses |
| 06/20/2013 | WO2013090387A1 Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds |
| 06/20/2013 | WO2013090369A1 Novel heterocyclic compounds useful in sirtuin binding and modulation |
| 06/20/2013 | WO2013090357A1 Hemostatic agents and methods of use |
| 06/20/2013 | WO2013090321A1 Vasoconstrictor for use in the treatment of abnormal uterine bleeding |
| 06/20/2013 | WO2013090319A2 Treatment of type i and type ii diabetes |
| 06/20/2013 | WO2013090278A2 Intranasal dexmedetomidine compositions and methods of use thereof |
| 06/20/2013 | WO2013090260A1 Nicotinic receptor targeted compounds and compositions |
| 06/20/2013 | WO2013090227A1 Benzisothiazol-3(1h)-one-5-sulfonyl derivatives as chemokine receptor modulators |
| 06/20/2013 | WO2013090210A1 Metalloenzyme inhibitor compounds |
| 06/20/2013 | WO2013090196A1 Combinations of azilsartan and chlorthalidone for treating hypertension black patients |
| 06/20/2013 | WO2013090117A1 A multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen |
| 06/20/2013 | WO2013089986A1 Improved denaturants for sympathomimetic amines |